An interventional study of YQD (Yìqì Jiànpí Decoction) and Plant-derived Lactobacillus in Constipation and Slow Transit Constipation, sponsored by First People's Hospital Of Lin'an District, Hangzhou. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-12.
Sponsored by First People's Hospital Of Lin'an District, Hangzhou · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Constipation with a site in China — 35 open to participants now, 37 under way, 1 of them phase 3. Constipation · China.
Among the 109 studies in Constipation with a site in China, this one is the 26th largest by enrollment of the 93 interventional ones that give a count, is one of 15 that started in 2025, is one of 56 with no phase, and was the 106th registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →35 of the 109 studies in Constipation with a site in China are open now. Recruiting first, the newest first:
Wecare Probiotics Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Wecare Probiotics Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Wecare Probiotics Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Tongji Hospital · Sites in China
Ages 18–75
Eli Lilly and Company · Sites in China, United States, Belgium and 5 more countries
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 23 · Phase 3 9 · Phase 4 3
First in 2004; this study’s year is marked. 15 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 120 is above the median of 75 across 885 interventional studies indexed under Constipation.
Median enrollment 100 across the 93 interventional studies, 278 across the 16 observational. Of the 50 that completed or were terminated, 6 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 109 have an industry lead sponsor. The 10 most frequent:
First People's Hospital Of Lin'an District, Hangzhou is the lead sponsor of 2 studies on the registry; none are open to participants now.
First People's Hospital Of Lin'an District, Hangzhou has 1 study filed under Constipation — fewer than ten, so there is no comparison to draw.
12 of the studies in Constipation with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07277907Phase 3Third Military Medical UniversityEfficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation | 2027-10-31 |
| NCT07507955Wecare Probiotics Co., Ltd.Probiotics for Constipation Relief in Adults | 2026-11-30 |
| NCT07765004Wecare Probiotics Co., Ltd.Probiotics Improve Constipation | 2026-12-15 |
| NCT07648394China-Japan Friendship HospitalResearch on the Efficacy and Mechanism of Shouhui Tongbian Capsules in Treating Postoperative Constipation of Benign Anal and Rectal Diseases Based on Gut Microbiota Analysis | 2026-12-31 |
| NCT07387952Peking Union Medical College HospitalThe Safety and Efficacy of Fecal Microbiota Transplantation Combined With Nutritional Intervention in the Treatment of Functional Constipation:a Pilot Study | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 109 studies in Constipation with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Slow transit constipation (STC) is a common and difficult-to-treat subtype of chronic constipation, characterized by reduced colonic motility and delayed stool passage. Current treatments often provide limited long-term relief, and many patients relapse after stopping medication. This study aims to evaluate whether combining a traditional Chinese herbal formula (Yìqì Jiànpí Decoction, YQD) with plant-derived Lactobacillus probiotics provides better and more sustained relief than either treatment alone or standard prokinetic therapy.
A total of 120 eligible patients with STC will be randomly assigned to four groups in a 1:1:1:1 ratio: (1) YQD + Lactobacillus + mosapride; (2) YQD + mosapride; (3) Lactobacillus + mosapride; (4) mosapride alone. The treatment lasts 8 weeks. The primary outcome is the change in Constipation Severity Score from baseline to week 8. Secondary outcomes include quality of life, colonic transit time, gut microbiota changes, and relapse rate during a 6-month follow-up period.
This study will provide evidence on whether an integrative TCM-probiotic strategy offers superior and more durable benefits for STC patients.
This is a single-center, prospective, assessor-blinded, parallel-group, superiority randomized controlled trial with a 1:1:1:1 allocation ratio. The study is conducted at the Department of Colorectal Surgery, The First People's Hospital of Lin'an District, Hangzhou, China.
Study Population: Adult patients (aged 18-75 years) diagnosed with slow transit constipation (STC) according to Rome IV criteria, with delayed colonic transit confirmed by a colon transit study (retention of ≥20% of markers at 72 hours). Key exclusion criteria include outlet obstruction constipation, secondary constipation due to organic diseases, history of abdominal surgery (except appendectomy or cholecystectomy), severe systemic illness, pregnancy or lactation, known allergy to any herbal ingredient or Lactobacillus preparation, and use of medications affecting gastrointestinal motility within 4 weeks before screening.
Interventions: All four groups receive a background therapy of mosapride citrate 5 mg three times daily for 8 weeks. On top of that: (1) Group A receives YQD (one dose daily) + plant-derived Lactobacillus (compound Lactobacillus tablets, 3 tablets twice daily); (2) Group B receives YQD + placebo for Lactobacillus; (3) Group C receives Lactobacillus + placebo for YQD; (4) Group D receives placebo for both YQD and Lactobacillus. The herbal decoction consists of 12 herbs: Cistanche deserticola (Roucongrong) 15 g, Atractylodes macrocephala (Baizhu) 15 g, Astragalus membranaceus (Huangqi) 20 g, Cynanchum wilfordii (Geshangiao) 15 g, Scrophularia ningpoensis (Xuanshen) 12 g, Raphanus sativus (Laifuzi) 15 g, Dioscorea opposita (Shanyao) 12 g, Galli Gigerii Endothelium Corneum (Jineijin) 15 g, Sesamum indicum (Heizhima) powder 12 g, Cyathula officinalis (Chuanniuxi) 15 g, Massa Medicata Fermentata (Shenqu) 15 g, and Colla Corii Asini (Ejiao) 12 g. One dose is decocted and concentrated to 100 mL, taken once daily in the morning.
Outcome Measures: The primary outcome is the change from baseline to week 8 in the Constipation Severity Score (CSS), which evaluates stool frequency, consistency, straining, abdominal pain, and use of aids. Secondary outcomes include: (1) change in Patient Assessment of Constipation Quality of Life (PAC-QOL) scores; (2) colonic transit measured by percentage of retained markers at 72 hours; (3) gut microbiota quantification via 16S rRNA PCR for Escherichia coli, Lactobacillus, and Bifidobacterium; (4) relapse rate during 6-month follow-up (assessed at 1, 3, and 6 months post-treatment); and (5) adverse events graded per CTCAE v5.0.
Sample Size: Based on pilot data, the mean CSS reduction in the triple-combination group is expected to be 6.0 (SD 3.5), versus 3.5 (SD 3.0) in the mosapride-alone group. To detect a difference of 2.5 points with 80% power and a two-sided alpha of 0.05, accounting for a 20% dropout rate, 30 patients per group (total 120) are required.
Statistical Analysis: Primary analysis will be on an intention-to-treat (ITT) basis; per-protocol analysis will be sensitivity. Baseline characteristics will be compared using ANOVA or chi-square tests. The primary outcome (change in CSS) will be analyzed by ANCOVA with baseline CSS as covariate and treatment group as fixed factor, followed by post-hoc pairwise comparisons with Bonferroni correction. Secondary continuous outcomes will be analyzed similarly. Relapse rates will be compared using chi-square tests. Repeated measures will use mixed-effects models. Missing data will be handled by multiple imputation. Two-sided p \< 0.05 will be considered statistically significant.
Ethics and Dissemination: The protocol has been approved by the Medical Ethics Committee of The First People's Hospital of Lin'an District, Hangzhou (approval number: LAYY-EC-2024-037). Written informed consent will be obtained from all participants. Results will be submitted for publication in a peer-reviewed journal and presented at national and international conferences.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive Yìqì Jiànpí Decoction (YQD) once daily, plant-derived Lactobacillus tablets (3 tablets twice daily), and mosapride citrate 5 mg three times daily for 8 weeks.
Dietary Supplement: YQD (Yìqì Jiànpí Decoction) · Dietary Supplement: Plant-derived Lactobacillus · Drug: Mosapride Citrate
Participants receive Yìqì Jiànpí Decoction (YQD) once daily and mosapride citrate 5 mg three times daily for 8 weeks. (No probiotics)
Dietary Supplement: YQD (Yìqì Jiànpí Decoction) · Drug: Mosapride Citrate
Participants receive plant-derived Lactobacillus tablets (3 tablets twice daily) and mosapride citrate 5 mg three times daily for 8 weeks. (No herbal decoction)
Dietary Supplement: Plant-derived Lactobacillus · Drug: Mosapride Citrate
Participants receive mosapride citrate 5 mg three times daily for 8 weeks as active comparator. (No herbal decoction, no probiotics)
Drug: Mosapride Citrate
A 12-herb traditional Chinese medicine formula consisting of Cistanche deserticola (Roucongrong) 15 g, Atractylodes macrocephala (Baizhu) 15 g, Astragalus membranaceus (Huangqi) 20 g, Cynanchum wilfordii (Geshangiao) 15 g, Scrophularia ningpoensis (Xuanshen) 12 g, Raphanus sativus (Laifuzi) 15 g, Dioscorea opposita (Shanyao) 12 g, Galli Gigerii Endothelium Corneum (Jineijin) 15 g, Sesamum indicum (Heizhima) powder 12 g, Cyathula officinalis (Chuanniuxi) 15 g, Massa Medicata Fermentata (Shenqu) 15 g, and Colla Corii Asini (Ejiao) 12 g. One dose is immersed in 1000 mL distilled water for 30 min, boiled, then simmered for 30 min, filtered; the residue is re-boiled with another 1000 mL, combined, and concentrated to 100 mL. Patients take the entire 100 mL once daily in the morning for 8 weeks.
Commercially available compound Lactobacillus tablets containing ≥10⁹ CFU of plant-derived Lactobacillus strains per tablet. Patients take 3 tablets twice daily (morning and evening) for 8 weeks.
Mosapride citrate 5 mg tablets taken orally three times daily before meals for 8 weeks.
Change in Constipation Severity Score (CSS)
The Constipation Severity Score (CSS) is a validated instrument that evaluates five dimensions of constipation: stool frequency, stool consistency, straining, abdominal pain, and use of aids to defecation. The total score ranges from 0 (minimum) to 39 (maximum), with higher scores indicating greater constipation severity. The outcome is measured as the change from baseline to week 8 (Week 8 score minus Baseline score).
Time frame: Baseline to Week 8
Change in Patient Assessment of Constipation Quality of Life (PAC-QOL) Score
PAC-QOL is a 28-item questionnaire assessing constipation-related quality of life across four subdomains: physical discomfort, psychosocial discomfort, worries and concerns, and satisfaction. Total scores range from 0 to 4, with higher scores indicating worse quality of life.
Time frame: Baseline to Week 8
Change in Colonic Transit Time - Percentage of Retained Markers at 72 Hours
Colonic transit is assessed using a radiopaque marker method. Participants ingest a capsule containing 20 markers on Day 1, and a plain abdominal X-ray is taken at 72 hours. The percentage of retained markers is calculated. A retention rate of ≥20% at 72 hours confirms slow transit constipation.
Time frame: Baseline to Week 8
Change in Gut Microbiota Quantification
Fecal samples are collected at baseline and week 8. DNA is extracted and 16S rRNA PCR quantification is performed for Escherichia coli, Lactobacillus, and Bifidobacterium. Results are expressed as CFU/g of wet stool.
Time frame: Baseline to Week 8
Relapse Rate During 6-Month Follow-Up
Relapse is defined as recurrence of constipation symptoms meeting Rome IV criteria or CSS returning to ≥50% of baseline score. Follow-up assessments are conducted at 1, 3, and 6 months post-treatment.
Time frame: Month 1, Month 3, and Month 6 post-treatment
Incidence of Treatment-Related Adverse Events
Adverse events are graded according to CTCAE v5.0 and recorded throughout the 8-week intervention period and 6-month follow-up. Safety is assessed by the number and severity of reported adverse events.
Time frame: Week 0 through Month 6 post-treatment
Plan to share: No — Individual participant data (IPD) will not be shared. The results of this study will be disseminated through publication in a peer-reviewed journal.
Ran from Jan 2025 to primary completion in Jun 2026, 17 months.
Of 245 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 17 months is close to that.
Counting every sponsor, half of 316 studies reached it within 14 months; a quarter within 6 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First People's Hospital Of Lin'an District, Hangzhou